Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?

Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the United States Food and Drug Administration (US FDA) approvals of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bitting, Rhonda L., Armstrong, Andrew J., George, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Consise Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210626/
https://www.ncbi.nlm.nih.gov/pubmed/22084621
http://dx.doi.org/10.4137/CMO.S5977
Descripción
Sumario:Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the United States Food and Drug Administration (US FDA) approvals of sipuleucel-T, cabazitaxel, and abiraterone acetate, all based on improvement in overall survival, the landscape for management of men with metastatic CRPC has dramatically changed. In this review we will discuss the pivotal clinical trial data leading to these approvals, with particular focus on the unique indication for sipuleucel-T and the implications for optimal management and sequencing of treatment in this patient population.

Ejemplares similares